Skip to content

ETIMAR MEDICALE

Active
Private limited companyfounded 1998active for 28 yearsChemin de Saint-Amand 37, 6220 Fleurus, BelgiumKBO/BCE: BE 0463.001.487
Summary

ETIMAR MEDICALE has been active since 1998 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €2.4m and a net result of €447,958. Equity has been growing by about 6.1% per year since 2019. Its solvency ranks better than 95% of 783 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).

Overview

Official details

Source: KBO
Status
Active since 31-03-1998 Normal situation
Activity
Specialist medical practice NACE 86220and 1 other
Establishment unit
2.228.463.845 6220 Fleurus, since 16-03-1998
Financial year end
31 August
Peppol
Reachable since 04-12-2025

Board and ownership

Board

Financial position

95 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
< 0.1%
Annual accounts to 31-08-2025
Gross margin
€611,604
▲ 5.1%
Turnover
≈ €1.2m
estimated
Profit
€447,958
▲ 16.7%
Equity
€2.4m
▲ 12.6%
Total assets
€2.4m
▲ 11.9%
Employees on 31-08-2025
1
=
Score breakdownlowers riskLiquidity: current ratio 392.64, cash €527,833Equity €2.4m (99.7% of total assets)Sector: Human health activities (NACE 86)Size: 0.2 FTE, total assets €2.4mShow the evidence

Checked score

Score 2025
95 / 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 61% of micro companies in human health (NACE 86)
Financial strength · tick: 2024
Strong
Solvency 100=
equity 99.7% of total assets
Liquidity 77-19
short-term debt 0.3% · cash 21.9%
Profitability 92+1
return on assets 18.6%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median < 0.1% (24,173 companies, NACE 86, micro)
Last 24 months 12-2024: < 0.1% 01-2025: < 0.1%● unchanged vs 12-2024 02-2025: < 0.1%● unchanged vs 01-2025 03-2025: < 0.1%● unchanged vs 02-2025 04-2025: < 0.1%● unchanged vs 03-2025 05-2025: < 0.1%● unchanged vs 04-2025 06-2025: < 0.1%● unchanged vs 05-2025 07-2025: < 0.1%● unchanged vs 06-2025 08-2025: < 0.1%● unchanged vs 07-2025 09-2025: < 0.1%● unchanged vs 08-2025lowest value 10-2025: < 0.1%● unchanged vs 09-2025 11-2025: < 0.1%● unchanged vs 10-2025 12-2025: < 0.1%● unchanged vs 11-2025 01-2026: < 0.1%● unchanged vs 12-2025 02-2026: < 0.1%● unchanged vs 01-2026 03-2026: < 0.1%● unchanged vs 02-2026highest value 04-2026: < 0.1%● unchanged vs 03-2026 05-2026: < 0.1%● unchanged vs 04-2026 06-2026: < 0.1%● unchanged vs 05-2026 07-2026: < 0.1%● unchanged vs 06-2026 08-2026: < 0.1%● unchanged vs 07-2026 09-2026: < 0.1%● unchanged vs 08-2026 10-2026: < 0.1%● unchanged vs 09-2026 11-2026: < 0.1%● unchanged vs 10-2026
Credit of up to €220,000 on 30-day terms is acceptable
Short-term debt is 0.3% and cash 21.9% of total assets. 0.3% of the assets are financed with debt and provisions.
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 82% of them on solvency, 59% on liquidity, 49% on profitability and 56% on growth.

The bankruptcy probability was computed on 04-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

The probability rests on the annual accounts with balance sheet date 31-08-2025.

Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Five signals.
lowers riskneutral
lowers risk · Liquidity: current ratio 392.64, cash €527,833
NBB · annual accounts
lowers risk · Equity €2.4m (99.7% of total assets)
NBB · annual accounts
lowers risk · Sector: Human health activities (NACE 86)
KBO
lowers risk · Size: 0.2 FTE, total assets €2.4m
Companies of this size fail less often. How much that weighs depends on the rest of the company's profile.
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 31-08-2025 was due by 31-03-2026 and was filed on 03-03-2026, 28 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
28 days early
2024
42 days early
2023
39 days early
2022
24 days early
2021
36 days early
2020
42 days early
2019
76 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 7 accounts on average 41 days before the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 31-08-2026 is due by 31-03-2027. Nothing is late today. The company usually files around 23 February (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven months
Where today falls in the filing period
31-08-2026 year end05-11-2026 today31-03-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Key points

  • Positive: Higher solvency than 95% of companies in human healthsector median 58.0% · 783 companies 99.7% View
  • Positive: Filed on time since financial year 2018accounts within the deadline every year 8 years View
  • Positive: 7 profitable years in a rowprofit 2025: €447,958 7 years View

Recent changes

  1. · Gazette deed Resignation: Etienne MARCHAND (manager)Reappointment: Etienne MARCHAND (director) · Director discharge: Etienne MARCHAND
  2. · Gazette deed Incorporation
All 18 events

Comparable companies

These companies have the same main activity as ETIMAR MEDICALE: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €1.8m and €3.4m, founded between 1996 and 2002.

CompanyTotal assetsGross margin
ETIMAR MEDICALE Fleurus€2.4m€0.6m
DOKTERS DEWANDRE-NYSEN Hasselt€2.7m€0.7m
Blanckaert MD Ypres€2.7m€0.6m
DOKTERSPRAKTIJK LAUWERS EN VAN HOESTENBERGHE Genk€2.6m€0.5m
DR. CHRIST DECLERCK Izegem€1.8m€0.6m
PHRYNE Liège€2.0m€0.5m
DR. STEFAAN BAFORT Ostend€3.4m€0.6m
Full comparison

Key facts about ETIMAR MEDICALE

What is the company number of ETIMAR MEDICALE?
The company number of ETIMAR MEDICALE is 0463.001.487. The VAT number is the same number with BE in front: BE 0463.001.487.
Where is ETIMAR MEDICALE based?
The registered office is at Chemin de Saint-Amand 37, 6220 Fleurus.Company details
What does ETIMAR MEDICALE do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of ETIMAR MEDICALE?
ETIMAR MEDICALE is a private limited company (BV).
When was ETIMAR MEDICALE founded?
ETIMAR MEDICALE was founded on 31-03-1998.
Is ETIMAR MEDICALE still active?
Yes, ETIMAR MEDICALE is an active enterprise in the KBO register.
How many employees does ETIMAR MEDICALE have?
ETIMAR MEDICALE had an average of 0.2 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of ETIMAR MEDICALE?
The turnover in financial year 2025 is ≈ €1.2m. This figure is estimated from the gross margin of €611,604 and 40 comparable companies (NACE 862). It probably lies between €800,000 and €1.9m.
Is ETIMAR MEDICALE profitable?
In financial year 2025, ETIMAR MEDICALE made a profit of €447,958.
Where can I find the annual accounts of ETIMAR MEDICALE?
ETIMAR MEDICALE filed 27 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of ETIMAR MEDICALE due?
ETIMAR MEDICALE must file the annual accounts for financial year 2026 by 31-03-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.